Hanmi Partners RAF inhibitor HM95573 with Genentech in a deal worth US$910 M

By Jawala Prasad

Pharma Deals Review: Vol 2016 Issue 10 (Table of Contents)

Published: 12 Oct-2016

DOI: 10.3833/pdr.v2016.i10.2200     ISSN: 1756-7874

Section: Licensing



Adding to its spree of out-licensing deals, Hanmi has convinced oncology leader Roche to partner in developing its early phase pan-RAF (rapidly accelerated fibrosarcoma) inhibitor, HM95573, in a deal worth up to US$910 M including an upfront payment of US$80M...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details